Philip Siberg
Chief Executive Officer
Q3 presentation
Philip Siberg, CEO of Senzime, presents the Q3 report for 2024.
CEO presentation
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Press release
Senzime reaches second milestone of Masimo collaboration with launch of integration to Iris Gateway
Press release
Senzime secures multiple new hospital contracts for its next-generation TetraGraph system
Regulatory PR
New number of shares and votes in Senzime AB (publ)
Financial info jan-sept 2024
Strong sales growth
Strong sales growth driven by accelerated sensor sales and increased usage of TetraGraph systems, as we continue to win more strategic hospital accounts in the US market.
44,4
Net sales, TSEK
78
Net sales, % increase
119
Sales of disposable sensors, % increase
63.9
Gross margin excluding depreciation, %
Annual Report 2023
Growth was driven by milestone new business deals and recurring sales of disposable sensors, as well as new clinical guidelines supporting Senzime’s products.
Download PDFReports and presentations archive
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.